GPT and acute myeloid leukemia: In collaboration with Altor BioScience, allogeneic PB-NK cells were combined with the NK priming ALT-801 IL-2/TCR fusion protein against AML (NCT01478074, Additional file 3: Table S3, row 6), but the trial was withdrawn due to low feasibility.